IonoJet™
Diabetic Foot Ulcers
Phase 3Active
Key Facts
About Origin
Origin Life Sciences is pioneering a novel drug delivery platform that converts atmospheric air into a targeted nitric oxide plasma stream for therapeutic use. The company's lead program targets diabetic foot ulcers, with a planned pivotal clinical trial as the pathway to FDA approval for the IonoJet™ device. Beyond wound care, the technology has broad potential applications across dermatology, infection control, dentistry, and respiratory conditions, positioning it as a versatile platform in the biologics and medical device space.
View full company profileTherapeutic Areas
Other Diabetic Foot Ulcers Drugs
| Drug | Company | Phase |
|---|---|---|
| PEP Biologic™ | Intent Biologics | Unknown |
| TOP-N53 | Topadur Pharma | Phase 2 |
| FGF-1 | Zhittya Genesis Medicine | Phase 2 |
| CXCL12 Formulation for DFU | ViCapsys | Pre-clinical |
| CYP-006 | Cynata Therapeutics | Preclinical |
| NovoSorb BTM | PolyNovo | Clinical Investigation |
| EPIFIX® / AMNIOFIX® | MiMedx Group | Post-Market Study |
| Dermagraft | Organogenesis | Approved/Commercial |